Is a low dose of hepatitis B vaccine enough for a rapid vaccination scheme?

Ru-Xiang Wang, Greet Boland, Ying Guo, Shao-Ping Lei, Chang-Hong Yang, Juan Chen, Jie Tian, Jin-Ying Wen, Ke-Hong Du, Jan van Hattum, Gijsbert C. de Gast

Ru-Xiang Wang, Ying Guo, Juan Chen, Shenyang Center for Disease Control and Prevention, Shenyang 110031, Liaoning Province, China
Greet Boland, Jan van Hattum, Department of Gastroenterology, University Hospital Utrecht, Netherlands
Shao-Ping Lei, Hospital of Institute of Shenyang Electricity Power, Shenyang 110031, Liaoning Province, China
Chang-Hong Yang, Dongling District Anti-epidemic Station, Dongling District, Shenyang 110031, Liaoning Province, China
Jie Tian, Shenyang No.4 Hospital, Shenyang 110031, Liaoning Province, China
Jin-Ying Wen, Shenyang 606 Hospital, Shenyang 110031, Liaoning Province, China
Ke-Hong Du, Shenzhen Kangtai Biological Products Company, Shenzhen 518000, Guangdong Province, China
Gijsbert C. de Gast, Netherlands Cancer Institute, Amsterdam, Netherlands

Correspondence to: Dr. Ru-Xiang Wang, Shenyang Center for Disease Control and Prevention, 37 Qishanzhong Road, Huanggu District, Shenyang 110031, China. rxwtxh@pub.sy.ln.cn
Telephone: +86-24-86853243  Fax: +86-24-86863778
Received: 2003-04-12  Accepted: 2003-06-11

Abstract

AIM: To determine whether or not a low dose of HB vaccine can be effectively used in the rapid vaccination.

METHODS: Rapid vaccination (0, 1, 2 months) with low dose (5 µg) or routine dose (10 µg) HB vaccine was studied in 250 subjects (130 school children and 120 university students). Serum from all the participants was tested for HBsAg, anti-HBs and anti-HBc at 1, 3 and 7 months after the first dose of vaccination and all subjects were serum HBV marks negative before the vaccination. Non-responders to a complete initial vaccination from university students were given an additional vaccination with 10 µg of HB vaccine and their serum anti-HBs was tested again one month later.

RESULTS: One month after the third dose of vaccination (third month) sero-conversion rates and geometric mean titer (GMTs) were significantly (P<0.01) higher in the routine dose (resp. 89 % and 106.8) than in the low dose group (resp. 72 % and 59.5). Sero-conversion rates and GMTs were maintained stable for another 4 months in both groups. After an additional vaccination to non-responders with 10 µg HB vaccine, 17/23 subjects (13/15 from those vaccinated with 5 µg vaccine and 4/8 from those vaccinated with 10 µg vaccine) became anti-HBs positive, yielding similar sero-conversion rates for both dose groups.

CONCLUSION: Higher sero-conversion rates and GMTs were reached in those vaccinated with 10 µg HB vaccine than in those vaccinated with 5 µg HB vaccine after a complete vaccination with a 0, 1, 2 month scheme. But the subjects vaccinated with 5 µg vaccine can also reach the similar sero-conversion rate after an additional vaccination.

INTRODUCTION

Although hepatitis B vaccine has been available for 20 years, hepatitis B nowadays remains prevalent in the world, especially in a majority of the developing countries. In China, 5 µg of vaccine (Merck) has been used in the HB vaccination for several years and acquired acceptable results. The long-term effectiveness of low-dose HB vaccine immunization in the infancy has been observed, but that in school children or adults remains to be determined. It is known that protective anti-HBs antibody titers can generally be reached in 80-90 % of individuals vaccinated with 10 µg vaccine according to a 0, 1, 2 month vaccination scheme. Considering of the relative length of the current HB vaccination scheme and the availability of low dose HB vaccine in the market, it seemed, therefore, worthwhile to test a routine dose (10 µg) vaccination in a rapid scheme (0, 1, 2 months) compared to a low dose (5 µg) vaccination. We here report that significantly higher seroconversion rates and GMTs are reached in those vaccinated with a 10 µg dose vaccination than those vaccinated with 5 µg dose vaccination after 3 months from the initial dose. School children and university students showed no significant differences apart from a more rapid response in school children.

MATERIALS AND METHODS

Two hundred and fifty subjects (130 school children aged 8-10 years old and 120 university students aged 18-20 years old) with negative HB marks (HBsAg, anti-HBs, anti-HBc) were included in the study. One hundred and thirty subjects (72 school children and 58 university students) nominated as low dose group and were vaccinated with 5 µg HB vaccine, 120 subjects (55 school children and 65 university students) named as routine dose group received 10 µg HB vaccine (5 µg dose x 2) respectively according to a 0, 1, 2 month vaccination scheme. All non-responding university students after a complete initial vaccination series were given a fourth dose with 10 µg HB vaccine at the 8th month. All injections were given intramuscularly at the site of deltoid muscle. The HB vaccine used in this study is 5 µg yeast recombinant HB vaccine (Lot no: 2990104-1, from Merck), provided by Kangtai Biological Pharmaceutical Company, China.

Blood samples that were collected from all vaccinees for three times performed were used to detect serum anti-HBs (Ausb EIA, No 642841 M401) at month 1, 3 and 7 after the first dose of vaccination respectively. The third month serum specimen from all non responders after the initial vaccination was tested for HBsAg and anti-HBc by ELISA (Lizon Kit, China) in order to make sure that they are real no-responders to HB vaccine and not HBV carriers. Those with negative tests

World J Gastroenterol 2003; 9(10): 2353-2355
received a fourth dose of vaccine at 8th month after vaccination and were again tested for serum anti-HBs one month later.

RESULTS

128/130 subjects in low dose group were tested for serum anti-HBs levels one month after the first dose of vaccination and only 114 subjects were available for the test one month after the third vaccination. The anti-HBs sero-conversion rate and GMT in this group was 71.9 % and 9.5 respectively (Table 1). 116/120 subjects in the routine group were tested for anti-HBs levels one month after the first dose of vaccination and only 110 subjects were available for the test one month after the third dose of vaccination. A significantly higher anti-HBs sero-conversion rate (89.1 %, \(P<0.01\)) and GMT (106.8, \(P<0.01\)) in routine dose group were observed after the third dose of vaccination compared with that in low dose group. At the seventh month the sero-conversion rate and GMT persisted at similar level to that after the second dose of vaccination.

Table 1  Seroconversion rate and GMT induced by low and routine dose of vaccines

| Dose of vaccine | Time after first injection | n  | Sero-conversion rate (%) | GMT |  \\
|-----------------|---------------------------|----|-------------------------|-----|------|
| 5µg             | 1\(^{st}\) time           | 128| 12.5                    | 59.5|  \\
|                 | 2\(^{nd}\) time           | 114| 71.9                    | 59.5|  \\
|                 | 3\(^{rd}\) time           | 113| 68.9                    | 58.5|  \\
| 10µg            | 1\(^{st}\) time           | 116| 19.0                    | 71.9|  \\
|                 | 2\(^{nd}\) time           | 110| 89.1\(^{t}\)            | 106.8|  \\
|                 | 3\(^{rd}\) time           | 98 | 91.8\(^{t}\)            | 94.6|  \\

\(^{t}\)P <0.01 vs. 5µg group.

Twenty three non-responding university students (15 vaccinated with 5 µg vaccine and 8 with 10 µg vaccine) were given a fourth dose of 10 µg HB vaccine after completion of the initial vaccination. Of these individuals, 13/15 non-responders in the low dose group and 4/8 non-responders in the routine dose group responded with anti-HBs one month after the additional dose. As a result of this additional vaccination, serum conversion rate in the low dose group was nearly similar to that in the routine dose group (95.2 % vs 92.9 %, Figure 1).

Figure 1 Seroconversion rate before and after a booster.

DISCUSSION

Since the introduction of hepatitis B vaccination in the early 1980s, the safety and immunogenicity of the plasma-derived and yeast-derived hepatitis B vaccines have been well demonstrated\(^{1-12}\). However, the disease remains a global problem. The failure of obtaining a complete 3 doses HB vaccination due to the length of the scheme probably contributes to the current prevalence of hepatitis B in the developing countries. Clearly, the protection against hepatitis B could be improved if a shorter vaccination regimen of achieving protective anti-HBs levels in >90 % of vaccinees was available. Our results clearly showed that with a rapid vaccination scheme (0, 1, 2 months) using 10 µg HB vaccine, serum anti-HBs levels can be induced, while it can not be reached by using 5 µg of HB vaccine. The similar results were also reported previously by Carlsson et al\(^{13}\) who vaccinated some medical staff and compared the effects of intramuscular (1 m, 20 µg.) vaccination with the low-dose intradermal (i d, 2 µg) vaccination on their early sero-conversion rates according to a 0, 4, 8 week scheme or to an accelerated 0, 2, 6 week scheme. He concluded that when a rapid protection against hepatitis B virus (HBV) infection was needed, such as the post-exposure prophylaxis, low-dose i.d. vaccination schedule could not be used.

A study on evaluating the potential for developing rapid seroprotection was performed by Young et al\(^{14}\), beneficial results of a one month/two dose regimen with a novel triple antigen vaccine (Hepacare) have been achieved\(^{15}\). These results confirmed that an accelerated vaccination could be achieved with appropriate vaccinating protocols.

Low-dose vaccination has been proposed as a cost-saving strategy to implement mass vaccination of neonates with HB vaccine world-wide, particularly in developing countries. In a previous study, Shokri F compared the effectiveness of three doses of recombinant HB vaccine (Heberbiovac) in three different doses, among three groups of healthy Iranian neonates. His results showed that there were no significant differences in sero-protection rate and GMTs between the 10 and 5 µg dose recipients. Both parameters, however, were significantly lower in neonates vaccinated with a 2.5 µg vaccine dose\(^{12}\). Leroux-Roels G observed the immunogenicity and reactogenicity profiles of different doses of Engerix-B(R) (10 microg hepatitis B surface antigen) and Recombivax (R) (5 microg hepatitis B surface antigen), on a 0, 1, 6 month schedule in healthy adolescents. One month following the third dose of vaccination, seroprotection rates of Engerix-B and Recombivax vaccination were similar but the geometric mean titer was significantly higher in those vaccinated with Engerix-B than that with Recombivax\(^{15}\). Similar results were also reported that higher immunogenicity is usually related with higher vaccine dosages, especially in older adult population\(^{13-18}\). Our results showed that a higher dose (10 µg) of vaccine can induce much higher sero-conversion rate and higher GMTs compared with the reduced dose (5 µg) vaccination whereas the GMTs can be sustained for at least 5 months in both groups after the primary vaccination.

In most studies on immunocompetent subjects, 5 % to 10 % vaccinees failed to respond to HB vaccination. The possible reasons for lack of adequate antibody response have been well reported\(^{16-22}\). In order to confirm if the reduced dose of HB vaccination could cause a higher rate of non- or hypo-response to HB vaccine, we gave all non-responders an additional dose after the initial HB vaccination scheme and one month later, the majority of them converted into anti-HBs positive. The final sero-conversion rates of non-responders in low dose group and routine dose group were 95.2 % and 92.9 % respectively, showing that it is rather a hyporesponse to a lower dose of HB vaccine than a non-response as found earlier\(^{23-31}\). Based on the results, we conclude that it is better for adults to choose 10 µg HB vaccine, especially when a rapid vaccination program is needed.

REFERENCES

1. Kojouharova M, Teoharov P, Bahtchevanova T, Maeval, Eginlian
A, Deneva M. Safety and immunogenicity of a yeast-derived recombinant hepatitis B vaccine in Bulgarian newborns. Infection 2001; 29: 342-344

2 Liao SS, Li RC, Li H, Yang JY, Zeng XJ, Gong J, Wang SS, Li YP, Zhang KL. Long-term efficacy of plasma-derived hepatitis B vaccine among Chinese children: a 12-year follow-up study. World J Gastroenterol 1999; 5: 165-166

3 Li H, Li RC, Liao SS, Yang JY, Zeng XJ, Wang SS. Persistence of hepatitis B vaccine immune protection and response to hepatitis B booster immunization. World J Gastroenterol 1998; 4: 493-496

4 Rendl-Wagner P, Kundi M, Stemberger H, Wiedermann G, Holzmann H, Hofer M, Wiesinger K, Kollaritsch H. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001; 19: 2055-2060

5 Ozaki T, Mochizuki H, Ichikawa Y, Fukuzawa Y, Yoshida S, Morimoto M. Persistence of hepatitis B surface antibody levels after vaccination with a recombinant hepatitis B vaccine: a 3-year follow-up study. J Oral Sci 2000; 42: 147-150

6 Jain A, Mathur US, Jandwani P, Gupta RK, Kumar V, Kar P. A multicentric evaluation of recombinant DNA hepatitis B vaccine of Cuban origin. Trop Gastroenterol 2000; 21: 14-17

7 Al-Falih FZ, Al-Jefri M, Ramia S, Al-Rashed R, Arif M, Rezeq M, Al-Torafi I, Baksh M, Mishkhah A, Makki O, Al-Freih H, Mirdad S, Al-Juma A, Yasir T, Al-Swaimel A, Ayoula A. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. J Infect 1999; 38: 167-170

8 Li H, Li RC, Liao SS, Gong J, Zeng XJ, Li YP. Long-term effectiveness of infant low dose hepatitis B vaccine immunization in Zhuang Minority Area in China. World J Gastroenterol 1999; 5: 122-124

9 Liu HB, Meng ZD, Ma JC, Han CO, Zhang YL, Xing ZC, Zhang YW, Liu YZ, Cao HL. A 12 year cohort study on the efficacy of plasma-derived hepatitis B vaccine in rural newborns. World J Gastroenterol 2000; 6: 381-383

10 Li H, Wang L, Wang SS, Gong J, Zeng XJ, Li RC, Nong Y, Huang YK, Chen XR, Huang ZN. Research on optimal immunization strategies for hepatitis B in different endemic areas in China. World J Gastroenterol 2000; 6: 392-394

11 Zeng XJ, Yang GH, Liao SS, Chen AP, Tan J, Huang ZJ, Li H. Survey of coverage, strategy and cost of hepatitis B vaccination in rural and urban areas of China. World J Gastroenterol 1999; 5: 320-323

12 Shokri F, Jalifarzadeh A. High seroprotection rate induced by low doses of a recombinant hepatitis B vaccine in healthy Iranian neonates. Vaccine 2001; 19: 4544-4548

13 Carlsson T, Struve J, Sonnerborg A, Weiland O. The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. Scand J Infect Dis 1999; 31: 93-95

14 Young MD, Rosenthal MH, Dickson B, Du W, Maddrey WC. A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine. Vaccine 2001; 19: 3437-3443

15 Leroux-Roels G, Abraham B, Fournieu M, De Clercq N, Safary A. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents. Vaccine 2000; 19: 937-942

16 Treadwell TL, Keeffe EB, Lake J, Read A, Friedman LS, Goldman IS, Howell CD, DeMedina M, Schiff ER, Jensen DM. Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med 1993; 95: 584-588

17 de Rave S, Heijtink RA, Bakker-Bendik M, Boot J, Schalm SW. Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers. Vaccine 1994; 12: 532-534

18 Bennett RG, Powers DC, Remsburg RE, Scheve A, Clements ML. Hepatitis B virus vaccination for older adults. J Am Geriatr Soc 1996; 44: 699-703

19 Yucesoy B, Sleijfer SA, Kashon M, Garssen J, de Gruijl FR, Boland GJ, van Hattum J, Simeonova PP, Luster MI, van Lier H. IL-1beta gene polymorphisms influence hepatitis B vaccination. Vaccine 2002; 20: 3193-3196

20 Jabaaei L, van Hattum J, Vingerhoets JJ, Oostveen FG, Duivenvoorden HJ, Balieux RE. Modulation of immune response to rDNA hepatitis B vaccination by psychological stress. J Psychosom Res 1996; 41: 129-137

21 Sleijfer SA, Yucesoy B, Kashon M, Garssen J, de Gruijl FR, Boland GJ, Van Hattum J, Luster MI, Van Lier H. Cytokine polymorphisms play a role in susceptibility to ultraviolet B-induced modulation of immune responses after hepatitis B vaccination. J Immunol 2003; 170: 3423-3428

22 Goldwater PN. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997; 15: 353-356

23 Wismans P, van Hattum J, Stelling T, Poel J, de Gast GC. Effect of supplementary vaccination in healthy non-responders to Hepatitis B vaccination. Hepatogastroenterology 1988; 35: 78-79

24 Wismans P, van Hattum J, Murdean HC, Endeman H, Poel J, de Gast GC. Is booster injection with hepatitis B vaccine necessary in healthy responders? J Hepatol 1988; 8: 236-240

25 Zaruba K, Grob PJ, Bolla K. Thymopentin as adjuvant therapy to hepatitis B vaccination in formerly non-or hyporesponding hemodialysis patients. Surv Immunol Med 1985; 4: S102-S106

26 Maruyama S, Sata M, Ishii K, Atomo Y, Ono K, Matuda T, Suzuki H, Muraoka H, Nakano H, Hino K. Hepatitis B vaccination in alcoholics. Kansenshogaku Zasshi 1989; 63: 27-34

27 Fabrizi F, Andruilli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12: 1204-1211

28 Hollinger FB. Factors Influencing the Immune Response to Hepatitis B Vaccine, booster dose guidelines and vaccine protocol recommendations. Am J Med 1989; 87: 3A-365

29 Erenson S, Biligic A, Arda B, Ozer O. Low-dose intramuscular hepatitis B vaccination in medical students: 4-year follow-up. Infection 2002; 30: 303-305

30 Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B antigen. Hepatology 1999; 30: 954-959

31 Clemens R, Sanger R, Kruppenschroer J, Hobel W, Stanbury W, Bock HL, Jilg W. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule results of a post-marketing surveillance. Vaccine 1997; 15: 349-352

Edited by Wang XL